Does intravenous GSK2586881 improve hemodynamics and inflammatory markers in patients with pulmonary arterial hypertension?
In a small pilot study, intravenous augmentation of ACE2 with GSK2586881 was well tolerated and improved pulmonary hemodynamics and inflammatory markers in patients with PAH.
intravenously).Superoxide dismutase 2 (SOD2) and inflammatory gene expression were identified as markers of Mas1 activation. After confirming reduced plasma ACE2 activity in human PAH, five patients were enrolled in the trial. GSK2586881 was well tolerated with significant improvement in cardiac output and pulmonary vascular resistance. GSK2586881 infusion was associated with reduced plasma markers of inflammation within 2-4 h and increased SOD2 plasma protein at 2 weeks.PAH is characterised by reduced ACE2 activity. Augmentation of ACE2 in a pilot study was well tolerated, associated with improved pulmonary haemodynamics and reduced markers of oxidant and inflammatory mediators. Targeting this pathway may be beneficial in human PAH.
Hemnes et al. (Fri,) studied this question.